ibandronic acid has been researched along with Hangman Fracture in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 13 (38.24) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 2 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Chen, LH; Ma, WJ; Wang, WY; You, RX | 1 |
| Hagino, H; Hashimoto, J; Ito, M; Mizunuma, H; Nakamura, T; Nakano, T; Tobinai, M | 1 |
| Barr, C; Day, BM; Felsenberg, D; Harris, S; Masanauskaite, D; Miller, PD; Recker, RR; Reginster, J; Silverman, S | 1 |
| Ohashi, S; Ono, K; Tanaka, S | 1 |
| Shiraishi, A | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Reid, IR | 1 |
| Hashimoto, J; Nakamura, T; Nakano, T; Tobinai, M; Yamamoto, M; Yoshida, S | 1 |
| Hashimoto, J; Ito, M; Nakamura, T; Tobinai, M; Yoshida, S | 1 |
| Keating, GM | 1 |
| Hochberg, MC | 1 |
| Dimai, HP; Dobnig, H; Fahrleitner-Pammer, A; Hauge, E; Obermayer-Pietsch, BM; Pieber, TR; Pilz, S; Piswanger-Soelkner, JC; Portugaller, RH; Prenner, G; Tscheliessnigg, KH | 1 |
| Adami, S; Delmas, PD; Huss, H; Miller, PD; Patel, KM; Recker, RR; Schimmer, RC | 1 |
| Tobinai, M | 1 |
| Boyer, KM; Esses, SI; Finkelstein, J; Goldberg, MJ; Hitchcock, K; Jenkins, J; Keith, M; McGuire, R; Sluka, P; Turkelson, CM; Watters, WC; Wies, JL; Woodard, E | 1 |
| Adler, G; Herdt, K; Klaus, J; Reinshagen, M; von Boyen, GB; von Tirpitz, C | 1 |
| Dorst, A; Faber, H; Ibach, K; Preuss, J; Ringe, JD | 1 |
| Dorst, A; Faber, H; Ibach, K; Ringe, JD; Sorenson, F | 1 |
| Kuwahara, T; Suzuki, M; Tanaka, Y; Yamada, T | 1 |
| Chesnut, CH; Christiansen, C; Delmas, PD; Emkey, R; Gilbride, J; Recker, RR; Schimmer, RC; Skag, A; Stakkestad, JA | 1 |
| Chesnut, CH; Christiansen, C; Delmas, PD; Felsenberg, D; Gilbride, J; Hoiseth, A; Huss, H; Recker, R; Schimmer, RC; Skag, A; Stakkestad, JA | 1 |
| Wallace, DJ | 1 |
| Baylink, DJ; Chesnut, CH; Emkey, R; Ettinger, MP; Harris, ST; Miller, PD; Recker, RR; Schimmer, RC; Wasnich, RD; Watts, NB | 1 |
| Adami, S; Bolognese, MA; Bonvoisin, B; Civitelli, R; Cooper, C; Delmas, PD; Dumont, E; Felsenberg, D; Kendler, DL; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA | 1 |
| Bolognese, MA; Bonvoisin, B; Cooper, C; Delmas, PD; Felsenberg, D; Hughes, C; Kendler, DL; Lewiecki, EM; Luckey, M; Macovei, L; Mairon, N; McClung, MR; Miller, PD; Recker, RR; Reginster, JY; Stakkestad, JA | 1 |
| Armbrecht, G; Felsenberg, D; Miller, P; Papapoulos, SE; Schimmer, RC; Wilson, K | 1 |
| Fassbender, WJ; Stumpf, UC | 1 |
| Hashimoto, J; Oshima, H; Tanaka, I | 1 |
16 review(s) available for ibandronic acid and Hangman Fracture
| Article | Year |
|---|---|
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Topics: Denosumab; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Teriparatide; Zoledronic Acid | 2023 |
Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Spinal Fractures; United States | 2014 |
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide | 2014 |
[Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate].
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Durapatite; Haplorhini; Humans; Ibandronic Acid; Infusions, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Rats; Spinal Fractures | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
Ibandronate: A Review in Japanese Patients with Osteoporosis.
Topics: Administration, Intravenous; Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Japan; Lumbar Vertebrae; Osteoporosis; Risedronic Acid; Spinal Fractures | 2016 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[Ibandronate].
Topics: Administration, Oral; Bone Density Conservation Agents; Clinical Trials, Phase II as Topic; Diphosphonates; Drug Administration Schedule; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures | 2011 |
[Ibandronate].
Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Ibandronic Acid; Osteoclasts; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Spinal Fractures | 2004 |
Rapid prevention of vertebral fractures associated with osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2005 |
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase I as Topic; Diphosphonates; Dogs; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Randomized Controlled Trials as Topic; Rats; Spinal Fractures | 2006 |
[New bone density conservation agents for osteoporosis under research and development: Ibandronate].
Topics: Administration, Oral; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Drug Design; Humans; Ibandronic Acid; Injections, Intravenous; Osteoporosis; Randomized Controlled Trials as Topic; Research; Spinal Fractures | 2007 |
13 trial(s) available for ibandronic acid and Hangman Fracture
| Article | Year |
|---|---|
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Japan; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Risedronic Acid; Spinal Fractures; Time Factors; Treatment Outcome | 2013 |
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Kidney Function Tests; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Risedronic Acid; Spinal Fractures; Vitamin D | 2016 |
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Diphosphonates; Female; Femoral Neck Fractures; Femur Neck; Humans; Ibandronic Acid; Japan; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures; Spine | 2017 |
Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
Topics: Acid Phosphatase; Adult; Antacids; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Cholecalciferol; Collagen Type I; Diphosphonates; Double-Blind Method; Heart Transplantation; Humans; Ibandronic Acid; Isoenzymes; Lumbar Vertebrae; Male; Middle Aged; Radiography; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Time Factors; Transplantation, Homologous | 2009 |
Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Spinal Fractures | 2010 |
Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Calcium Citrate; Cholecalciferol; Crohn Disease; Delayed-Action Preparations; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Ibandronic Acid; Incidence; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prevalence; Sodium Fluoride; Spinal Fractures; Treatment Outcome; Young Adult | 2011 |
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
Topics: Aged; Back Pain; Bone Density; Calcaneus; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Injections, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prospective Studies; Spinal Fractures | 2003 |
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
Topics: Aged; Back Pain; Body Height; Bone Density; Diphosphonates; Drug Administration Schedule; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Spinal Fractures | 2003 |
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Resorption; Collagen; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Hip; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteocalcin; Peptides; Risk Factors; Spinal Fractures; Treatment Outcome | 2004 |
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Topics: Aged; Body Height; Bone and Bones; Bone Density; Diphosphonates; Double-Blind Method; Female; Femur; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Pelvic Bones; Prospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome | 2004 |
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Resorption; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Ibandronic Acid; Middle Aged; North America; Osteoporosis; Postmenopause; Spinal Fractures; White People | 2005 |
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Collagen; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risk Factors; Spinal Fractures; Spine; Treatment Outcome | 2005 |
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Humans; Ibandronic Acid; Incidence; Internationality; Lumbar Vertebrae; Middle Aged; North America; Osteoporosis, Postmenopausal; Risk; Severity of Illness Index; Spinal Fractures; Time Factors | 2005 |
5 other study(ies) available for ibandronic acid and Hangman Fracture
| Article | Year |
|---|---|
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
The treatment of symptomatic osteoporotic spinal compression fractures.
Topics: Bone Density Conservation Agents; Calcitonin; Combined Modality Therapy; Diphosphonates; Evidence-Based Medicine; Fractures, Compression; Humans; Ibandronic Acid; Nerve Block; Organometallic Compounds; Osteoporotic Fractures; Pain Measurement; Spinal Fractures; Thiophenes; Vertebroplasty | 2011 |
Ibandronate (Boniva): a new oral bisphosphonate.
Topics: Administration, Oral; Diphosphonates; Dose-Response Relationship, Drug; Ibandronic Acid; Scleritis; Spinal Fractures; Spinal Injuries; Uveitis | 2005 |
[DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Minimally Invasive Surgical Procedures; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Recombinant Proteins; Spinal Fractures; Teriparatide; Thiophenes | 2006 |